Week in Review: Fosun Pharma Buys Israeli Laser Company for $240 Million

May 4, 2013 -- Shanghai Fosun Pharma, Chindex and a private equity partner will spend $240 million to buy a 95.6% stake in Alma Lasers, an Israeli medical device company; Ascletis, a China-US drug developer, in-licensed China rights to a next-generation HIV protease inhibitor from Janssen R&D Ireland; Zhejiang Huahai Pharma raised $126 million in a secondary offering to help pay for a new $240 million manufacturing facility; 3SBio rescheduled the vote on its controversial take-private offer for May 24, 2013; Richard Soll, PhD, of WuXi AppTec, said WuXi considers all its clients as partners no matter how the business relationship is structured; OrbusNeich, a Hong Kong cardiovascular device maker, won a German patent suit over stent technology against Boston Scientific; Li Ka-Shing, the richest man in Asia, gave $31 million to Oxford University in England to fund a new drug discovery and healthcare delivery institute; and China’s Ministry of Finance allocated $48.6 million in an effort to control the spread of the H7N9 avian flu. More details....

Stock Symbols: (SH: 600196; HK: 02196) (NSDQ: CHDX) (SHA: 600521) (NSDQ: SSRX) (NYSE: WX) (NYSE: BSX)